ABL Diagnostics to present at Paris midcap investor event

ABL Diagnostics will meet investors at the European Main MidCap Event Paris 2026 on Sept. 30-Oct. 1 at the Four Seasons Hotel George V. The company plans to discuss recent developments, growth strategy and international expansion across molecular diagnostics and life sciences services.

Why it matters: - ABL Diagnostics is using the Paris event to give investors a direct update on its growth plans and expanding life sciences footprint. - The meetings could help the company reinforce awareness of its molecular diagnostics, virology and biosafety businesses with institutional investors.

What happened: - ABL Diagnostics said it will participate in the European Main MidCap Event Paris 2026 on Sept. 30 and Oct. 1, 2026, at the Four Seasons Hotel George V in Paris. - The event is organized by CF&B Communication and brings together listed companies and international institutional investors for one-to-one meetings and leadership sessions. - ABL Diagnostics management will be available for one-to-one investor meetings during the event. - Investors can find more information about the event online.

The details: - The company plans to present recent developments, its growth strategy and its outlook during the meetings. - Discussions will cover ABL Diagnostics’ changing business scope, international expansion and stronger positioning in molecular diagnostics, virology, viral safety and services for life sciences clients. - Investors interested in meeting management can contact ABL Diagnostics at contact@abldiagnostics.com or +33 (0)3 87 17 81 56. - Meeting requests can also go through CF&B Communication contact Margaux Desnus at m.desnus@cfbcom.fr or +33 (0)6 43 53 91 79. - The company also lists contact information on its website. - ABL Diagnostics is based in Woippy, France, and trades on Euronext Paris, compartment B, under the ticker ABLD and ISIN FR001400AHX6.

Between the lines: - The event gives ABL Diagnostics a venue to frame its story around recurring revenue, broader microbiology offerings and its move beyond core diagnostics. - The company’s messaging suggests a push to connect its recent portfolio changes with a larger international growth narrative. - ABL Diagnostics says its activities now include TEXCELL-related virology, biosafety and biopharmaceutical development services, alongside its molecular testing business.

What's next: - ABL Diagnostics will hold investor meetings during the Sept. 30-Oct. 1 conference. - The company is expected to use the event to highlight product lines including UltraGene PCR testing, DeepChek DNA sequencing, syndromic PCR tests and the Nadis patient record system. - The company’s broader offering also includes CDL Pharma products and services under an intra-group strategy agreement that began in the second half of 2025. - ABL Diagnostics says Nadis is used in more than 200 hospitals in France for HIV and hepatitis care.

The bottom line: - ABL Diagnostics is heading into a key investor forum with a pitch centered on expansion, international reach and a wider life sciences platform.